We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
South Korea's drug regulator has granted approval for a Phase IIa trial of Helixmith's investigational gene therapy Engensis for treating amyotrophic lateral sclerosis (ALS), reported The Korea Herald.